Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-25-267040
Filing Date
2025-11-05
Accepted
2025-11-05 16:28:18
Documents
89
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q inva-20250930.htm   iXBRL 10-Q 3787608
2 EX-31.1 inva-ex31_1.htm EX-31.1 14653
3 EX-31.2 inva-ex31_2.htm EX-31.2 14654
4 EX-32 inva-ex32.htm EX-32 23102
  Complete submission text file 0001193125-25-267040.txt   16089995

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT inva-20250930.xsd EX-101.SCH 1968138
92 EXTRACTED XBRL INSTANCE DOCUMENT inva-20250930_htm.xml XML 3573281
Mailing Address 1350 OLD BAYSHORE HIGHWAY SUITE 400 BURLINGAME CA 94010
Business Address 1350 OLD BAYSHORE HIGHWAY SUITE 400 BURLINGAME CA 94010 6502389600
Innoviva, Inc. (Filer) CIK: 0001080014 (see all company filings)

EIN.: 943265960 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-30319 | Film No.: 251454496
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)